Pyxis Oncology, Inc. Debt Securities, Available-for-sale, Amortized Cost
Pyxis Oncology, Inc. (PYXS) had Debt Securities, Available-for-sale, Amortized Cost of $14.14 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $14.14M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $35.25M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $51.38M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $92.62M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $14.14M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $35.25M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $51.38M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $92.62M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $107.29M 10-Q · filed 2025-05-15 |
| 2023-09-30 | $118.36M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $116.85M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $95.59M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |